CDXS Stock Analysis: Buy, Sell, or Hold?
CDXS - Codexis, Inc.
$1.67
0.09 (5.70%)
â˛
5d:
+7.05%
30d:
-16.08%
90d:
-33.99%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When CDXS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CDXS is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CDXS is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CDXS is currently trading at $1.67, which is considered fair relative to its 30-day fair value range of $1.41 to $2.01. From a valuation perspective, the stock is trading at a discount (Forward PE: -5.2) compared to its historical average (16.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CDXS is in a strong uptrend. The price is approaching resistance at $1.70. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.7% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.33 (+279.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CDXS is in a strong uptrend. The price is approaching resistance at $1.70. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.7% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.33 (+279.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.41 -
$2.01
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
81.9%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.7%)
- BULLISH: Trading 279.2% below Wall St target ($6.33)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 48/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.41 -
$2.01
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.46
Resistance Level
$1.70
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.22
Wall Street Target
$6.33
(+279.2%)
Revenue Growth (YoY)
-2.7%
Profit Margin
-39.6%
PE vs Historical
-5.2 vs 16.6
CHEAP
Share & Embed Analysis
Last updated: August 23, 2026 2:05 AM ET
Data refreshes hourly during market hours. Next update: 3:05 AM
Data refreshes hourly during market hours. Next update: 3:05 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CDXS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$125 | 41 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$101 | 50 HOLD |
|
SMMT
Summit Therapeutics PLC |
STRONG BUY
10 analysts |
$29 | 55 HOLD |
